Document is current

Any future updates will be listed below

Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer

Crossref DOI link: https://doi.org/10.1007/s12325-022-02178-2

Published Online: 2022-05-07

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark